Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Thu, 16 Jul 2026 07:05:00 -0400

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

Date: Thursday, August 6, 2026 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Webcast Access:

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Thu, 16 Jul 2026 07:05:00 -0400

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

Date: Thursday, August 6, 2026 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Webcast Access:

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Thu, 16 Jul 2026 07:05:00 -0400

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

Date: Thursday, August 6, 2026 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Webcast Access:

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Thu, 16 Jul 2026 07:05:00 -0400

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

Date: Thursday, August 6, 2026 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Webcast Access:

Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes

Mon, 29 Jun 2026 07:02:45 -0400

Relmada Therapeutics, Inc. (Nasdaq: RLMD) was added to the Russell 2000® and Russell 3000® indexes effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes semi-annual reconstitution.

The Russell 3000® tracks the 3,000 largest publicly traded U.S. companies and represents approximately 98% of the investable U.S. equity market. The Russell 2000® covers 2,000 small-cap companies within that universe and is widely used by institutional investors as a benchmark for small-cap performance.

"Being added to the Russell 2000® and Russell 3000® is a meaningful accomplishment that reflects Relmada's ongoing progress. The robust 12-month data for NDV-01 in

Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes

Mon, 29 Jun 2026 07:02:45 -0400

Relmada Therapeutics, Inc. (Nasdaq: RLMD) was added to the Russell 2000® and Russell 3000® indexes effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes semi-annual reconstitution.

The Russell 3000® tracks the 3,000 largest publicly traded U.S. companies and represents approximately 98% of the investable U.S. equity market. The Russell 2000® covers 2,000 small-cap companies within that universe and is widely used by institutional investors as a benchmark for small-cap performance.

"Being added to the Russell 2000® and Russell 3000® is a meaningful accomplishment that reflects Relmada's ongoing progress. The robust 12-month data for NDV-01 in

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Mon, 29 Jun 2026 07:00:00 -0400

CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.

The Russell 3000® is a leading benchmark for broad U.S. equity market performance. It tracks the 3,000 largest publicly traded U.S. companies and represents roughly 98% of

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Mon, 29 Jun 2026 07:00:00 -0400

CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.

The Russell 3000® is a leading benchmark for broad U.S. equity market performance. It tracks the 3,000 largest publicly traded U.S. companies and represents roughly 98% of

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Mon, 29 Jun 2026 07:00:00 -0400

CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.

The Russell 3000® is a leading benchmark for broad U.S. equity market performance. It tracks the 3,000 largest publicly traded U.S. companies and represents roughly 98% of

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Mon, 29 Jun 2026 07:00:00 -0400

CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.

The Russell 3000® is a leading benchmark for broad U.S. equity market performance. It tracks the 3,000 largest publicly traded U.S. companies and represents roughly 98% of

H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)

Tue, 23 Jun 2026 06:50:17 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $12.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD).
The analyst commented: "We recently spoke with three academic and community urology KOLs to better understand how physicians are interpreting Relmada’s NDV-01 dataset, the relevance of TRCG-011 for Pivotal RESCUE study, and the evolving regulatory and commercial bar in NMIBC. The feedback reinforces our view that NDV-01 remains differentiated as a sustained-release Gem/Doce formulation, but also sharpens the evidentiary bar heading into RESCUE. Across the KOLs, the central message is that TRCG-011 is supportive and hypothesis-generating, but not definitive, given its small,

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 22 Jun 2026 17:33:00 -0400
si-local-file:///var/storage/secattach/20260622/26674238.html

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 22 Jun 2026 17:33:00 -0400
si-local-file:///var/storage/secattach/20260622/26674238.html

Form S-8 RELMADA THERAPEUTICS,

Thu, 18 Jun 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260618/26665961.html

Form S-8 RELMADA THERAPEUTICS,

Thu, 18 Jun 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260618/26665961.html

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.
The analyst comments "What’s new? We are initiating coverage of Relmada Therapeutics with a Buy rating and $12 price target, with our thesis centered on NDV-01 as a differentiated sustained-release intravesical formulation of gemcitabine/docetaxel, or Gem/Doce, for non-muscle invasive bladder cancer. In our view, NDV-01 is best understood as a next-generation delivery platform for a familiar and increasingly validated intravesical chemotherapy backbone rather than a wholly novel therapeutic modality. This distinction matters because Gem/Doce has already gained meaningful

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.
The analyst comments "What’s new? We are initiating coverage of Relmada Therapeutics with a Buy rating and $12 price target, with our thesis centered on NDV-01 as a differentiated sustained-release intravesical formulation of gemcitabine/docetaxel, or Gem/Doce, for non-muscle invasive bladder cancer. In our view, NDV-01 is best understood as a next-generation delivery platform for a familiar and increasingly validated intravesical chemotherapy backbone rather than a wholly novel therapeutic modality. This distinction matters because Gem/Doce has already gained meaningful

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.
The analyst comments "What’s new? We are initiating coverage of Relmada Therapeutics with a Buy rating and $12 price target, with our thesis centered on NDV-01 as a differentiated sustained-release intravesical formulation of gemcitabine/docetaxel, or Gem/Doce, for non-muscle invasive bladder cancer. In our view, NDV-01 is best understood as a next-generation delivery platform for a familiar and increasingly validated intravesical chemotherapy backbone rather than a wholly novel therapeutic modality. This distinction matters because Gem/Doce has already gained meaningful

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.
The analyst comments "What’s new? We are initiating coverage of Relmada Therapeutics with a Buy rating and $12 price target, with our thesis centered on NDV-01 as a differentiated sustained-release intravesical formulation of gemcitabine/docetaxel, or Gem/Doce, for non-muscle invasive bladder cancer. In our view, NDV-01 is best understood as a next-generation delivery platform for a familiar and increasingly validated intravesical chemotherapy backbone rather than a wholly novel therapeutic modality. This distinction matters because Gem/Doce has already gained meaningful

Relmada appoints Michael Quirk as senior advisor for sepranolone program

Thu, 11 Jun 2026 07:02:13 -0400

Relmada Therapeutics Inc. (NASDAQ: RLMD) appointed Michael Quirk as Senior Advisor for its sepranolone program. Quirk brings over 20 years of neuroscience drug discovery and development experience, including his previous role as Chief Scientific Officer at Sage Therapeutics.
Sepranolone is a GABAA receptor modulator being developed to treat Prader-Willi Syndrome and other central nervous system disorders. The drug selectively antagonizes allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling.
"His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology," said

Relmada appoints Michael Quirk as senior advisor for sepranolone program

Thu, 11 Jun 2026 07:02:13 -0400

Relmada Therapeutics Inc. (NASDAQ: RLMD) appointed Michael Quirk as Senior Advisor for its sepranolone program. Quirk brings over 20 years of neuroscience drug discovery and development experience, including his previous role as Chief Scientific Officer at Sage Therapeutics.
Sepranolone is a GABAA receptor modulator being developed to treat Prader-Willi Syndrome and other central nervous system disorders. The drug selectively antagonizes allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling.
"His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology," said

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Thu, 11 Jun 2026 07:00:00 -0400

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.

CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Thu, 11 Jun 2026 07:00:00 -0400

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.

CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Thu, 11 Jun 2026 07:00:00 -0400

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.

CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Thu, 11 Jun 2026 07:00:00 -0400

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics.

CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development

StreetInsider.com News Articles

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes

Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Form S-8 RELMADA THERAPEUTICS,

Form S-8 RELMADA THERAPEUTICS,

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Relmada appoints Michael Quirk as senior advisor for sepranolone program

Relmada appoints Michael Quirk as senior advisor for sepranolone program

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program